Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-03-01
2011-03-01
Saeed, Kamal A (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S254090, C514S323000, C514S414000, C544S144000, C544S373000, C546S201000, C548S455000, C548S468000
Reexamination Certificate
active
07897602
ABSTRACT:
Indolinone compounds of formula (I) or (II):wherein A, R1, R2, R3, R4, R5, R6, R7, and n are defined herein. Also disclosed are methods for decreasing the activity of a protein kinase and for treating a protein kinase-related disease, such as cancer, with these compounds.
REFERENCES:
patent: 6114371 (2000-09-01), Tang
patent: 6130238 (2000-10-01), Tang
patent: 6350754 (2002-02-01), Tang
patent: 6579897 (2003-06-01), Tang
patent: 6878733 (2005-04-01), Shenoy
patent: 2002/0187978 (2002-12-01), Tang
patent: 2003/0069297 (2003-04-01), Cui
patent: 2003/0119819 (2003-06-01), Liang
patent: 2004/0186160 (2004-09-01), Tang
patent: 2004/0266843 (2004-12-01), Howlett
patent: 2006/0094682 (2006-05-01), Westwick
patent: 2006/001954 (2006-01-01), None
Philip Cohen, The development and therapeutic potential of protein kinase inhibitors, 1999, Current Opinion in Chemical Biology, 3, pp. 459-465.
Lala et al., Role of nitric oxide in tumor progression: Lessons from experimental tumors, 1998, Cancer and Metastasis Reviews, 17(1), pp. 91-106.
Golub et al., Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring, 1999, Science, vol. 286, pp. 531-537.
Sun, et al., “Identification of Substituted 3-[4,5,6,7-Tetrahydro=1H-indo1-2-y1) methylene]-1,3dihydroindol-2 ones as Growth Factor Receptor Inhibitors for VEGF-R2 (Flk-1/KDR), FGF-R1, and PDGF-Rβ Tyrosine Kinases”, J. Med. Chem. 2000, 43, 2655-2663.
Guan, et al., “Design and Synthesis of Aminopropyl Tetrahydroindole-based Indolin-2-ones as Selective and Potent Inhibitors of Src and Yes Tyrosine Kinase”, Biorganic & Medicinal Chemistry Letters 14 (2004) 187-190.
Chang Jia-Ming
Chen Paonien
Chiang Chao-Cheng
Chuang Shih-Hsien
Huang Jiann-Jyh
Bianchi Kristin
Development Center for Biotechnology
Occhiuti Rohlicek & Tsao LLP
Saeed Kamal A
LandOfFree
Indolinone compounds as kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Indolinone compounds as kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Indolinone compounds as kinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2728328